Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity

Abstract The bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 has been previously identified as a more potent analog of dexrazoxane (ICRF-187), a drug used in clinical practice against anthracycline cardiotoxicity. However, the poor aqueous solubility of ICRF-193 has precluded its further in...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hana Bavlovič Piskáčková, Hana Jansová, Jan Kubeš, Galina Karabanovich, Nela Váňová, Petra Kollárová-Brázdová, Iuliia Melnikova, Anna Jirkovská, Olga Lenčová-Popelová, Jaroslav Chládek, Jaroslav Roh, Tomáš Šimůnek, Martin Štěrba, Petra Štěrbová-Kovaříková
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2021-02-01
Edice:	Scientific Reports
On-line přístup:	https://doi.org/10.1038/s41598-021-83688-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!